Final Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR Positive, HER2 Low/Negative Breast Cancer: TROPION-Breast01 Phase 3 Trial
Topline Results from TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan The TROPION-Breast01 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) against investigator’s choice chemotherapy has reported that while the treatment met its primary endpoint for progression-free survival (PFS), it did not…
Xofluza Phase III Results Show Significant Reduction in Influenza Transmission
Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced positive topline results from the Phase III CENTERSTONE study of Xofluza® (baloxavir marboxil). The study showed that a single oral dose of Xofluza significantly reduced the transmission of…
Prolucent Names New Sales Leaders for Healthcare Workforce Expansion
Prolucent®, a top provider of healthcare workforce optimization solutions, is excited to announce two key new hires to boost market expansion and sales growth. Jason Phibbs has been appointed Vice President of Growth, and Darryl Green will take on the…
InnoCare Secures Approval for ICP-248 AML Clinical Trial in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company specializing in cancer and autoimmune disease treatments, has received approval to conduct a clinical trial for its BCL2 inhibitor, ICP-248, in combination with azacitidine for acute myeloid leukemia (AML) in…
Tivic Health Gets IRB Approval for ncVNS Study, Prepares for Enrollment
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company specializing in bioelectronic medicine, announced it has received Institutional Review Board (IRB) approval from The Feinstein Institutes for the next phase of clinical work on its non-invasive cervical vagus nerve…
Aura Launches 1-Hour At-Home Health Check, Beyond Standard Blood Tests
Aura, a leader in personalized healthcare, has launched a groundbreaking at-home health check in New York. In just one hour, nurses conduct extensive blood work, imaging, cognitive assessments, and more, all from the comfort of your home. This holistic approach…
Alzprotect Reports Positive Results from Phase 2a PSP Study Extension
Alzprotect, a French biopharma company, has successfully completed the open-label extension (OLE) phase of its Phase 2a trial for AZP2006 (ezeprogind®) in treating Progressive Supranuclear Palsy (PSP). Results from the 6-month extension highlight AZP2006’s potential to stabilize or slow disease…
STEMCELL and Axion BioSystems Partner to Optimize Excitable Cell Culture and Analysis
Axion BioSystems and STEMCELL Technologies are excited to announce a strategic partnership that will see STEMCELL distributing Axion’s advanced Maestro Pro™ and Maestro Edge™ multielectrode array (MEA) systems across North America and Europe. The Maestro MEA systems will also remain…
Novostia Appoints New CEO and Secures CHF 5.6M Funding
Novostia, a leading medical technology company advancing a groundbreaking heart valve replacement, has announced a leadership change and secured CHF 5.6 million in funding. Soad El Ghazouani has been appointed as the new CEO, taking over from Alain Barbal, who…
Life Spine Publishes Study on Discectomy Performance: Endoscopic vs. MIS Tubular Approach in TLIF
Life Spine, Inc., a medical device company specializing in products for spinal disorder treatments, announced that the international peer-reviewed journal Spine has published a new study comparing discectomy performance during Transforaminal Lumbar Interbody Fusion (TLIF) using an endoscopic technique versus…
MATTER Chosen to Lead BARDA Digital Health Hub
MATTER, a leading healthcare incubator and innovation hub, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) as the Digital Health Hub for the BARDA Accelerator Network. BARDA, part of the U.S. Department of Health and Human…
MedTech Innovator Chosen to Lead BARDA Accelerator Hub
MedTech Innovator (MTI), the world’s largest accelerator for medical technology companies, announced that its BioTools Innovator (BTI) program has been chosen as the Enabling Technologies Hub for the next generation of the Biomedical Advanced Research and Development Authority (BARDA) Accelerator…